LIGNAMED
LignaMed's experienced team of scientists and life science professionals are dedicated to developing breakthrough treatments for asthma, organ transplant viability, and fibrosis. LignaMed plans to complete preclinical studies on LGM2605 as a lung transplant device in 2021. LignaMed plans to submit a device package for a lung transplant in 2022. Clinical studies for asthma are scheduled to begin in 2022. There is no effective treatment for Th2-low asthma, which affects 170,000 Americans.
LIGNAMED
Industry:
Health Care Life Science Medical Device Product Research
Founded:
2013-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.lignamed.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving Global Site Tag Sitelinks Search Box
Official Site Inspections
http://www.lignamed.com
- Host name: 104.21.82.37
- IP address: 104.21.82.37
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "LignaMed"
Home - LignaMed LLC
Company Overview. LignaMed's experienced team of scientists and life science professionals is dedicated to developing breakthrough treatments for asthma, organ transplant viability, and …See details»
LignaMed - Crunchbase Company Profile & Funding
LignaMed's experienced team of scientists and life science professionals are dedicated to developing breakthrough treatments for asthma, organ transplant viability, and fibrosis. …See details»
Who We Are - LignaMed LLC
Who We Are - LignaMed LLC. Chief Executive Officer. David Leach, MBA. David Leach is a former Merck executive with 25+ years’ experience in the life sciences. His expertise is in …See details»
LignaMed Company Profile 2024: Valuation, Funding & Investors
National Heart, Lung, and Blood Institute, National Aeronautics and Space Administration, National Institute for Allergy and Infectious Disease, and Penn Center for Innovation have …See details»
Lignamed, LLC Company Profile | Blue Bell, PA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Lignamed, LLC of Blue Bell, PA. Get the latest business insights from Dun & Bradstreet.See details»
LignaMed Company Profile - Office Locations, Competitors ... - Craft
LignaMed is a biotechnology company offering treatments for asthma, organ transplant viability, and fibrosis. Its lead candidate LGM2605 is a small molecule synthetic lignan with anti …See details»
Lignamed, LLC - VentureRadar
LignaMed, LLC, is biotechnology company developing breakthrough treatments for asthma, organ transplant viability and fibrosis. Lead candidate LGM2605 is a novel small molecule synthetic …See details»
Milestones - LignaMed LLC
Milestones - LignaMed LLC. Results from Preclinical Studies: LGM2605 significantly reduced disease progression in non-human primate asthma models. LGM2605 demonstrated safety in …See details»
Lignamed, LLC | SBIR.gov
LignaMed, LLC is a drug development company with a fast track strategy to approval of LGM2605, an oral small molecule for use as a radiation mitigating agent that reduces harmful …See details»
LignaMed - Crunchbase
LignaMed is committed to developing breakthrough treatments for asthma, organ transplant viability, and fibrosis.See details»
LignaMed - Products, Competitors, Financials, Employees, …
LignaMed is a life science company focused on the development of treatments in the healthcare industry. The company's main offerings include treatments for conditions such as asthma, …See details»
LignaMed - Overview, News & Similar companies | ZoomInfo.com
Dec 18, 2019 · LignaMed contact info: Phone number: (610) 631-1612 Website: www.lignamed.com What does LignaMed do? LignaMed, LLC, is biotechnology company …See details»
Firm | SBIR
LignaMed, LLC is developing a novel small molecule device, LGM2605, that will be utilized and administered via FDA approved ex vivo lung perfusion (EVLP), to improve lung function …See details»
LignaMed - Tech Stack, Apps, Patents & Trademarks - Crunchbase
LignaMed is committed to developing breakthrough treatments for asthma, organ transplant viability, and fibrosis.See details»
Product - LignaMed LLC
Lung Transplants. There is a need to rehabilitate and improve lung function and preserve donor lungs ex-vivo to increase the supply of viable lungs and improve outcomes for transplantation …See details»
BREAKTHROUGH TREATMENT FOR ASTHMA and LUNG …
A biopharmaceutical company focused on development of breakthrough treatments for lung diseases and conditions. •LGM2605, is a first in class, synthetic small molecule lignan with a …See details»
Optimization of LGM2605 for use as a device in lung transplant
Feb 10, 2020 · LignaMed is developing LGM2605 a small molecule medical device to improve the quality and number of donor lungs available for transplant. LGM2605 has the potential to save …See details»
LignaMed Announces Publication of Data on Lead Candidate …
Dec 19, 2019 · LignaMed, LLC, is biotechnology company developing breakthrough treatments for asthma, organ transplant viability and fibrosis. Lead candidate LGM2605 is a novel small …See details»
The aligned organization | McKinsey
Dec 1, 2014 · Achieving real alignment, where strategy, goals, and meaningful purpose reinforce one another, gives an organization a major advantage because it has a clearer sense of what …See details»
Development Plan - LignaMed LLC
LignaMed plans to submit device package for lung transplant in 2025. Submit IND Application to FDA. An IND submission for asthma is planned for 2025. Clinical Studies. Initiation of clinical …See details»